OPKO Health Sells Assets to Labcorp for Up to $872 Million

Under the terms of the deal, Opko Health will receive $722 million in cash upon completion, with the potential for an additional $150 million in contingent payments based on the performance of the divested operations. The transaction includes laboratory testing operations across clinical medicine, women's health, urology, and correctional facilities, alongside more than 80 patient service centers and the proprietary 4Kscore prostate cancer test. Labcorp projects that the acquired operations will generate approximately $250 million in revenue in the first year after the acquisition closes.

Led by Chairman and CEO Dr. Philip Frost, Opko Health aims to use the proceeds to streamline its organizational structure and refocus its resources on its biopharmaceutical development pipeline. This transaction follows previous divestitures of BioReference assets to Labcorp, which totaled $237 million in 2024 and approximately $192 million in 2025. Following the announcement, Opko Health's stock, which is traded on both the Tel Aviv and New York stock exchanges, surged between 20% and 25.64%. The completion of the sale remains subject to regulatory approvals and customary closing conditions.